# Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

> **NCT00766363** · PHASE1 · COMPLETED · sponsor: **FORUM Pharmaceuticals Inc** · enrollment: 49 (actual)

## Conditions studied

- Alzheimer's Disease
- Central Nervous System Diseases

## Interventions

- **DRUG:** EVP-6124 (0.1 mg/day)
- **DRUG:** EVP-6124 (0.3 mg/day)
- **DRUG:** EVP-6124 (1.0 mg/day)
- **DRUG:** Comparator: Placebo
- **DRUG:** Donepezil
- **DRUG:** Rivastigmine

## Key facts

- **NCT ID:** NCT00766363
- **Lead sponsor:** FORUM Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2012-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00766363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00766363, "Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00766363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*